Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR) Given Consensus Recommendation of “Moderate Buy” by Analysts

Shares of Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR) have received an average recommendation of “Moderate Buy” from the nineteen ratings firms that are covering the company, MarketBeat reports. Two equities research analysts have rated the stock with a sell rating, one has given a hold rating, thirteen have issued a buy rating and three have assigned a strong buy rating to the company. The average 1-year price target among analysts that have covered the stock in the last year is $106.75.

A number of equities research analysts recently weighed in on the stock. William Blair reaffirmed an “outperform” rating on shares of Structure Therapeutics in a research report on Monday, March 16th. Wall Street Zen downgraded shares of Structure Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, May 16th. Citizens Jmp lowered their price objective on shares of Structure Therapeutics from $120.00 to $113.00 and set a “market outperform” rating for the company in a research report on Friday, February 27th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Structure Therapeutics in a research report on Tuesday, April 21st. Finally, HC Wainwright reduced their target price on shares of Structure Therapeutics from $100.00 to $70.00 and set a “buy” rating for the company in a research note on Thursday, June 11th.

Structure Therapeutics Stock Up 4.9%

Shares of NASDAQ:GPCR opened at $45.00 on Thursday. Structure Therapeutics has a fifty-two week low of $15.80 and a fifty-two week high of $94.90. The firm has a 50-day simple moving average of $43.09 and a 200 day simple moving average of $57.53. The company has a market cap of $3.20 billion, a PE ratio of -51.72 and a beta of -1.35.

Structure Therapeutics (NASDAQ:GPCR) last announced its quarterly earnings data on Thursday, May 7th. The company reported ($0.35) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.39) by $0.04. As a group, research analysts forecast that Structure Therapeutics will post -1.64 EPS for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the company. Aberdeen Group plc boosted its stake in Structure Therapeutics by 46.1% during the 3rd quarter. Aberdeen Group plc now owns 586,869 shares of the company’s stock valued at $16,432,000 after purchasing an additional 185,245 shares during the period. Jefferies Financial Group Inc. acquired a new position in Structure Therapeutics during the 3rd quarter valued at about $4,770,000. Private Capital Advisors Inc. acquired a new position in Structure Therapeutics during the 3rd quarter valued at about $1,545,000. Capricorn Fund Managers Ltd acquired a new position in Structure Therapeutics during the 4th quarter valued at about $17,568,000. Finally, First Light Asset Management LLC boosted its stake in Structure Therapeutics by 61.5% during the 3rd quarter. First Light Asset Management LLC now owns 197,350 shares of the company’s stock valued at $5,526,000 after purchasing an additional 75,124 shares during the period. 91.78% of the stock is owned by institutional investors and hedge funds.

About Structure Therapeutics

Structure Therapeutics (NASDAQ:GPCR) is a clinical‐stage biotechnology company focused on the discovery and development of oral small‐molecule therapies that target G protein‐coupled receptors (GPCRs). Leveraging advances in structural biology, computational chemistry and medicinal chemistry, the company’s scientific platform is designed to optimize binding interactions and pharmacokinetic properties, with the goal of delivering innovative treatments for metabolic and inflammatory disorders.

The company’s pipeline comprises multiple programs in various stages of preclinical and clinical development.